Neuromod Medical launches Ireland’s first dedicated tinnitus telemedicine service

Neuromod Medical launches Ireland’s first dedicated tinnitus telemedicine service

Neuromod Medical has launched Ireland’s first telemedicine service dedicated to remote assessment, care and treatment of patients with tinnitus.

Telemedicine is the practice of providing medical and audiological care using electronic information and telecommunications technologies such as a laptop, tablet or mobile phone. Coinciding with World Hearing Day (Wednesday 3rd March), Neuromod Medical is delighted to announce the provision of quick access to tinnitus assessments.

Prior to today’s announcement, hundreds of tinnitus patients have already commenced their treatment journeys via the telemedicine offering.

Neuromod Medical, a wholly owned subsidiary of Neuromod Devices Limited, is a centre of excellence for tinnitus care that strives to reduce the impact tinnitus can have on patients by recognising the need for dedicated and expert clinicians to assess and advise on treatment options and if appropriate, offering treatment with the evidence-based, science-driven treatment medical device Lenire® or onward referral to the most appropriate expert.

Neuromod Medical is based at the Hermitage Medical Clinic in Dublin and offers patients the option to book appointments in-clinic or online. In recognition of the expanded offering, Neuromod Medical has welcomed five new employees, doubling the size of the clinical team.

Speaking on the launch of the tinnitus telemedicine service, Ms. Caroline Hamilton, Clinical Director of Neuromod Medical said: “At Neuromod Medical we are wholly focussed on personalised tinnitus care so we are delighted to launch our new services that will enable our patients to advance their tinnitus care in a matter of days. Patients can now go online and book a remote or in-clinic tinnitus assessment with a member of our clinical audiology team. During the secure video call, our experts will find out more about the nature and severity of the patient’s tinnitus and can formulate a treatment plan that will be appropriate for the individual, such as prescribing the Lenire tinnitus treatment system, referring the patient for a hearing aid or recommending the patient undertake other therapies such as CBT (cognitive behavioural therapy) or TRT (tinnitus retraining therapy).”

According to Dr Ross O’Neill, CEO of Neuromod Devices, the demand for telemedicine and other telehealth services has increased, particularly because patient consultations have been cancelled due to the impact of the COVID-19 pandemic.

Dr O’Neill said: “The vision for our remote tinnitus assessment service is to provide quick and easy access to treatment for tinnitus patients. In the past few months, studies have shown that tinnitus patients who contract COVID-19 can see a worsening of their condition . Furthermore, it has been shown that infection with COVID-19 can trigger tinnitus in those who never had it before. Recent studies have also shown that tinnitus is associated with a substantially higher risk of hearing loss within three years of diagnosis . Therefore, it has never been more important to have quick and easy access to tinnitus experts who can design a treatment plan to better manage the condition. We are seeing a pent-up demand for video appointments as we’ve had a significant number of patients book appointments since we made the service available online”.

People who suffer from tinnitus can now book a free welcome call with Neuromod Medical, at a date and time which suits them, by visiting

In October 2020, Neuromod announced it raised €10.5 million in an oversubscribed Series B financing round, which is being used to expand European commercialisation and scale-up manufacturing of the Lenire device to meet demand.

Tinnitus affects between 10 and 15% of the global population, and the lives of at least one in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.